China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study in China. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CMS-D005 in healthy and overweight and obese adult subjects.
Dual Agonist CMS-D005 Targets Metabolic Diseases
CMS-D005 is a dual agonist of the glucagon-like peptide-1 receptor (GLP-1 R) and the glucagon receptor (GCGR). It is under development for the treatment of obesity/overweight, metabolism-related steatohepatitis, type 2 diabetes, and other metabolism-related diseases. The drug candidate’s dual mechanism of action offers a potential new approach to managing these conditions, which are increasingly prevalent and can have significant health implications.
Clinical Study Design and Objectives
The clinical study will involve both healthy and overweight/obese adult subjects, providing valuable data on the drug’s performance in different populations. The objectives of the study include evaluating the drug’s safety profile, understanding its pharmacokinetic properties, and assessing its pharmacodynamic effects, which are crucial for determining its potential efficacy and suitability as a treatment option.-Fineline Info & Tech
